Lipid-Bound Vesicles for BMP2 Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The clinical application of bone morphogenetic protein 2 (BMP2) is challenging due to its poor binding to collagen type I sponge, leading to burst release and short residence times in vivo, resulting in undesirable off-target side-effects, especially when used off-label, highlighting the need for improved delivery methods that can safely and effectively deliver BMP2 and other extracellular signaling molecules.

Innovation Solution

Engineered lipid-bound vesicles are developed, where a secreted, cell surface receptor-binding signaling molecule like BMP2 is loaded into the lumen of lipid-bound vesicles, ensuring at least 25% to 99% of the molecule is contained within the vesicle, protected from enzymatic degradation, and capable of bypassing surface receptors to signal target cells effectively.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If BMP2 is delivered using collagen type I sponge, then BMP2 can be delivered to the target site, but the binding is poor resulting in burst release and short residence times

Engineering Contradiction:

Improvedelivery reliabilityVSAvoidresidence time

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent uses an engineered lipid-bound vesicle as an intermediary carrier to deliver BMP2. The vesicle comprises a lipid bilayer envelope with BMP2 loaded into the lumen, serving as a mediator between the delivery system and the target site. This intermediary approach solves the poor binding issue by replacing collagen type I sponge with a vesicle system that provides both stable delivery and prolonged residence time through its lipid bilayer structure.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs a lipid bilayer envelope (a flexible thin film structure) to encapsulate BMP2. This flexible shell provides protection while allowing controlled interaction with the biological environment, achieving both reliable delivery and extended residence time without the burst release problems associated with collagen sponges.

Inventive Principle:

Principle #30Flexible shells and thin films

2Reliability

If large pharmacological doses of BMP2 are used to compensate for poor binding, then adequate signaling can be achieved, but off-target side effects increase

Engineering Contradiction:

Improvesignaling efficacyVSAvoidoff-target side effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The engineered lipid-bound vesicle enables localized delivery of BMP2 to specific target sites. By controlling the localization and release of BMP2 from the vesicle, the system achieves adequate signaling efficacy at the target while minimizing exposure to non-target tissues, thereby reducing off-target side effects associated with high systemic doses.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The vesicle acts as a targeted delivery intermediary that directs BMP2 to specific cells or tissues. This mediator approach allows for lower overall dosing while maintaining effective local concentration at the target site, reducing the off-target effects that occur with large pharmacological doses used in untargeted delivery.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Ease of operation

If BMP2 is surface-bound on the vesicle, then it can interact with receptors, but it becomes vulnerable to proteolysis and inhibitory proteins

Engineering Contradiction:

Improvereceptor interaction capabilityVSAvoidprotection from degradation

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent places BMP2 inside the lumen of the lipid-bound vesicle, nesting the signaling molecule within the protective lipid bilayer envelope. This nested structure allows BMP2 to be protected from proteolysis and inhibitory proteins in the extracellular environment while still enabling receptor interaction through controlled mechanisms such as vesicle internalization or controlled release.

Inventive Principle:

Principle #7Nested doll (Nesting)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for targeted and prolonged delivery of BMP2, reducing off-target effects by encapsulating BMP2 within lipid-bound vesicles, which are protected from proteolysis and inhibitory proteins, thereby enhancing bone repair and regeneration while minimizing side-effects.

Implementation Method 1

Methodology Applied

Scientific EffectEncapsulation:

Implementation Method 2

Methodology Applied

Scientific EffectLipid bilayer encapsulation:

Data Source

PatentUS20240408029A1Loading of Extracellular Signaling Molecules Into Lipid-Bound Vesicles for Therapeutic Applications

Publication Date: 2024.12.12 CARNEGIE MELLON UNIV

AI summary

Provided herein are engineered lipid-bound vesicles for cytosolic delivery of an exogenous secreted, cell surface receptor-binding signaling molecule. Also provided herein are methods of making and using the engineered lipid-bound vesicles, and devices comprising the lipid-bound vesicles.